glutamine consumption
Recently Published Documents


TOTAL DOCUMENTS

32
(FIVE YEARS 12)

H-INDEX

12
(FIVE YEARS 1)

2022 ◽  
Vol 2022 ◽  
pp. 1-9
Author(s):  
Weihua Chen ◽  
Weifeng Wang ◽  
Jun Zhang ◽  
Guoqiang Liao ◽  
Jie Bai ◽  
...  

Traditional Chinese medicine (TCM) is widely used as an alternative therapy for cancer treatment in China. Glutamine catabolism plays an important role in cancer development. Qici Sanling decoction (QCSL) suppresses bladder cancer growth. However, the association between QCSL and glutamine catabolism remains unknown. In this study, different doses of QCSL were applied to T24 cells, followed by the measurements of cell viability and apoptosis using CCK-8 and Annexin V/PI assay, respectively. Furthermore, glutamine consumption was detected using the glutamine assay kit. QCSL was observed to inhibit cell growth and induced cell apoptosis in a dose-dependent manner. Analysis of glutamine consumption revealed that QCSL suppressed glutamine consumption in T24 cells. Furthermore, QCSL decreased the mRNA and protein levels of c-Myc, GLS1, and SLC1A5. All these effects induced by QCSL could be alleviated by c-Myc overexpression, indicating c-Myc was involved in the protective role of QCSL in bladder cancer. In addition, QCSL was found to inhibit tumor growth in the xenograft tumor model. The similar results were obtained in tumor samples that protein levels of c-Myc, GLS1, and SLC1A5 were decreased upon treatment with QCSL. In conclusion, QCSL suppresses glutamine consumption and bladder cancer cell growth through inhibiting c-Myc expression.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Boris Pantic ◽  
Daniel Ives ◽  
Mara Mennuni ◽  
Diego Perez-Rodriguez ◽  
Uxoa Fernandez-Pelayo ◽  
...  

AbstractPathological variants of human mitochondrial DNA (mtDNA) typically co-exist with wild-type molecules, but the factors driving the selection of each are not understood. Because mitochondrial fitness does not favour the propagation of functional mtDNAs in disease states, we sought to create conditions where it would be advantageous. Glucose and glutamine consumption are increased in mtDNA dysfunction, and so we targeted the use of both in cells carrying the pathogenic m.3243A>G variant with 2-Deoxy-D-glucose (2DG), or the related 5-thioglucose. Here, we show that both compounds selected wild-type over mutant mtDNA, restoring mtDNA expression and respiration. Mechanistically, 2DG selectively inhibits the replication of mutant mtDNA; and glutamine is the key target metabolite, as its withdrawal, too, suppresses mtDNA synthesis in mutant cells. Additionally, by restricting glucose utilization, 2DG supports functional mtDNAs, as glucose-fuelled respiration is critical for mtDNA replication in control cells, when glucose and glutamine are scarce. Hence, we demonstrate that mitochondrial fitness dictates metabolite preference for mtDNA replication; consequently, interventions that restrict metabolite availability can suppress pathological mtDNAs, by coupling mitochondrial fitness and replication.


PLoS ONE ◽  
2021 ◽  
Vol 16 (11) ◽  
pp. e0259241
Author(s):  
Ethan Emberley ◽  
Alison Pan ◽  
Jason Chen ◽  
Rosalyn Dang ◽  
Matt Gross ◽  
...  

Dysregulated metabolism is a hallmark of cancer that manifests through alterations in bioenergetic and biosynthetic pathways to enable tumor cell proliferation and survival. Tumor cells exhibit high rates of glycolysis, a phenomenon known as the Warburg effect, and an increase in glutamine consumption to support the tricarboxylic acid (TCA) cycle. Renal cell carcinoma (RCC) tumors express high levels of glutaminase (GLS), the enzyme required for the first step in metabolic conversion of glutamine to glutamate and the entry of glutamine into the TCA cycle. We found that RCC cells are highly dependent on glutamine for proliferation, and this dependence strongly correlated with sensitivity to telaglenstat (CB-839), an investigational, first-in-class, selective, orally bioavailable GLS inhibitor. Metabolic profiling of RCC cell lines treated with telaglenastat revealed a decrease in glutamine consumption, which was concomitant with a decrease in the production of glutamate and other glutamine-derived metabolites, consistent with GLS inhibition. Treatment of RCC cells with signal transduction inhibitors everolimus (mTOR inhibitor) or cabozantinib (VEGFR/MET/AXL inhibitor) in combination with telaglenastat resulted in decreased consumption of both glucose and glutamine and synergistic anti-proliferative effects. Treatment of mice bearing Caki-1 RCC xenograft tumors with cabozantinib plus telaglenastat resulted in reduced tumor growth compared to either agent alone. Enhanced anti-tumor activity was also observed with the combination of everolimus plus telaglenastat. Collectively, our results demonstrate potent, synergistic, anti-tumor activity of telaglenastat plus signal transduction inhibitors cabozantinib or everolimus via a mechanism involving dual inhibition of glucose and glutamine consumption.


2021 ◽  
Vol 11 (14) ◽  
pp. 6258
Author(s):  
Iván Martínez-Monge ◽  
Pere Comas ◽  
David Catalán-Tatjer ◽  
Jordi Prat ◽  
Antoni Casablancas ◽  
...  

One of the most important limitations of mammalian cells-based bioprocesses, and particularly hybridoma cell lines, is the accelerated metabolism related to glucose and glutamine consumption. The high uptake rates of glucose and glutamine (i.e., the main sources of carbon, nitrogen and energy) lead to the production and accumulation of large amounts of lactate and ammonia in culture broth. Lactate and/or ammonia accumulation, together with the depletion of the main nutrients, are the major causes of apoptosis in hybridoma cell cultures. The KB26.5 hybridoma cell line, producing an IgG3, was engineered with BHRF1 (KB26.5-BHRF1), an Epstein–Barr virus-encoded early protein homologous to the antiapoptotic protein Bcl-2, with the aim of protecting the hybridoma cell line from apoptosis. Surprisingly, besides achieving effective protection from apoptosis, the expression of BHRF1 modified the metabolism of the hybridoma cell line. Cell physiology and metabolism analyses of the original KB26.5 and KB26.5-BHRF1 revealed an increase of cell growth rate, a reduction of glucose and glutamine consumption, as well as a decrease in lactate secretion in KB26.5-BHRF1 cells. A flux balance analysis allowed us to quantify the intracellular fluxes of both cell lines. The main metabolic differences were identified in glucose consumption and, consequently, the production of lactate. The lactate production flux was reduced by 60%, since the need for NADH regeneration in the cytoplasm decreased due to a more than 50% reduction in glucose uptake. In general terms, the BHRF1 engineered cell line showed a more efficient metabolism, with an increase in biomass volumetric productivity under identical culture conditions.


2020 ◽  
pp. jcs.251645
Author(s):  
Leyao Shen ◽  
Deepika Sharma ◽  
Yilin Yu ◽  
Fanxin Long ◽  
Courtney Karner

Osteoblasts are the principal bone forming cells. As such, osteoblasts have enhanced demand for amino acids to sustain high rates of matrix synthesis associated with bone formation. The precise systems utilized by osteoblasts to meet these synthetic demands are not well understood. WNT signaling is known to rapidly stimulate glutamine uptake during osteoblast differentiation. Using a cell biology approach, we identified two amino acid transporters, Slc7a7 and Slc1a5, as the primary transporters of glutamine in response to WNT. Slc1a5 mediates the majority of glutamine uptake, whereas Slc7a7 mediates the rapid increase in glutamine uptake in response to WNT. Mechanistically, WNT signals through the canonical/β-catenin dependent pathway to rapidly induce Slc7a7 expression. Conversely, Slc1a5 expression is regulated by the transcription factor ATF4 downstream of the mTORC1 pathway. Targeting either Slc1a5 or Slc7a7 using shRNA reduced WNT induced glutamine uptake and prevented osteoblast differentiation. Collectively these data highlight the critical nature of glutamine transport for WNT induced osteoblast differentiation.


2020 ◽  
Author(s):  
Song Xiao ◽  
Wang Nai-Dong ◽  
Jin-Xiang Yan ◽  
Long Tian ◽  
Xiu-Rong Lu ◽  
...  

Abstract Background Angiopoietin-like proteins (ANGPTLs) 4 is key factor in the regulation of lipid and glucose metabolism in metabolic diseases. It also has been demonstrated highly expressed in cancers, but the regulation of energy metabolism on tumor remains to be determined.Methods Two different NSCLC cells A549 and H1299 were used to investigate the role of ANGPTLs 4 in energy metabolism by tracer technique and seahorse XF technology in ANGPTLs4 knockdown cell. RNA microarray and specific inhibitors were used in identification targets in overexpression ANGPTLs4 cells.Results Knockdown ANGPTLs4 could inhibit the energy metabolism and proliferation of NSCLC cells. Knockdown ANGPTLs4 had no significant effect on glycolysis, but affected the glutamine consumption and fatty acid oxidation. Knockdown ANGPTLs4 also significantly inhibited the growth of metastasis and energy metabolism of tumor in mice, but had a weak effect on glycolysis. RNA microarray analysis showed that ANGPTLs4 significantly affected GLS and CPT1. ANGPTLs4 overexpression cells exposed to glutamine deprivation, the effect on cell proliferation and energy metabolism were significantly decreased, but still has difference compared with normal NSCLC cells. ANGPTLs4 overexpression cells treated with GLS and CPT1 inhibitor at the same time, the regulatory effects on cell proliferation and energy metabolism were disappeared.Conclusions ANGPTLs4 could promote the glutamine consumption and fatty acid oxidation, but not glycolysis, and accelerated the energy metabolism in NSCLC.


2020 ◽  
Vol 2020 ◽  
pp. 1-12
Author(s):  
Yair Romero ◽  
Manuel Castillejos-López ◽  
Susana Romero-García ◽  
Alfonso Salgado Aguayo ◽  
Iliana Herrera ◽  
...  

A hypoxic microenvironment is a hallmark in different types of tumors; this phenomenon participates in a metabolic alteration that confers resistance to treatments. Because of this, it was proposed that a combination of 2-methoxyestradiol (2-ME) and sodium dichloroacetate (DCA) could reduce this alteration, preventing proliferation through the reactivation of aerobic metabolism in lung adenocarcinoma cell line (A549). A549 cells were cultured in a hypoxic chamber at 1% O2 for 72 hours to determine the effect of this combination on growth, migration, and expression of hypoxia-inducible factors (HIFs) by immunofluorescence. The effect in the metabolism was evaluated by the determination of glucose/glutamine consumption and the lactate/glutamate production. The treatment of 2-ME (10 μM) in combination with DCA (40 mM) under hypoxic conditions showed an inhibitory effect on growth and migration. Notably, this reduction could be attributed to 2-ME, while DCA had a predominant effect on metabolic activity. Moreover, this combination decreases the signaling of HIF-3α and partially HIF-1α but not HIF-2α. The results of this study highlight the antitumor activity of the combination of 2-ME 10 μl/DCA 40 mM, even in hypoxic conditions.


2020 ◽  
Vol 72 (6) ◽  
pp. 843-851
Author(s):  
Song Xiao ◽  
Yan Jin-xiang ◽  
Tian Long ◽  
Lu Xiu-rong ◽  
Gao Hong ◽  
...  

Animals ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 326 ◽  
Author(s):  
Ali Mujtaba Shah ◽  
Zhisheng Wang ◽  
Jian Ma

In the body of an animal, glutamine is a plentiful and very useful amino acid. Glutamine consumption in the body of animals in normal or disease conditions is the same or higher than the glucose. Many in vivo as well as in vitro experiments have been conducted to evaluate the importance of glutamine. Glutamine is a valuable nutrient for the proliferation of the lymphocytes. It also plays a crucial role in the production of cytokines, macrophages, phagocytic, and neutrophil to kill the bacteria. Most of the metabolic organs like the liver, gut, and skeletal muscles control the circulation and availability secretion of glutamine. In catabolic and hypercatabolic conditions, glutamine can turn out to be essential and plays a vital role in metabolism; however, availability may be compromised due to the impairment of homeostasis in the inter-tissue metabolism of amino acids. This is why the supplementation of glutamine is commonly used in clinical nutrition and is especially recommended to immune-suppressed persons. Despite this, in catabolic and hyper-catabolic conditions, it is challenging due to the amino acid concentration in plasma/bloodstream and glutamine should be provided via either the oral, enteral or parenteral route. However, the effect of glutamine as an immune-based supplement has been previously recognized as many research studies conducted in vivo and in-vitro evaluated the beneficial effects of glutamine. Hence, the present study delivers a combined review of glutamine metabolism in essential organs of the cell immune system. In this review, we have also reviewed the metabolism and action of glutamine and crucial problems due to glutamine supplementation in catabolic conditions.


Sign in / Sign up

Export Citation Format

Share Document